April 25, 2017 / 11:11 AM / 3 months ago

Drugmaker Biogen's revenue rises 3 percent

1 Min Read

April 25 (Reuters) - Biogen Inc reported a 3 percent rise in quarterly revenue, helped by higher-than-expected sales of its newly launched spinal muscular atrophy drug, Spinraza.

However, net income attributable fell to $747.6 million, or $3.46 per share, in the first quarter ended March 31, from $970.9 million, or $4.43 per share, a year earlier.

Total revenue rose to $2.81 billion from $2.73 billion. (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below